<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02039401</url>
  </required_header>
  <id_info>
    <org_study_id>VMALS-001 / B</org_study_id>
    <nct_id>NCT02039401</nct_id>
  </id_info>
  <brief_title>Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViroMed Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViroMed Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of intramuscular
      injections of VM202 at different injection sites in people with amyotrophic lateral
      sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with serious and non serious adverse events</measure>
    <time_frame>Throughout the nine month follow up</time_frame>
    <description>Adverse events (including serious adverse events, and adverse events leading to treatment discontinuation) throughout the 9 months follow-up will be described according to severity and to their relationship with the study drug and injection procedure. Descriptive statistics will be used to characterize safety parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatocyte Growth Factor (HGF) serum levels</measure>
    <time_frame>immediately pre-treatment on Day 0, immediately pre-treatment on Day 7, immediately pre-treatment on Day 14, immediately pre-treatment on Day 21, on Day 30, Day 60 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Copies of VM202 in whole blood</measure>
    <time_frame>Day 0, 7, 14, 21 (pre and post last injection), and Day 30, 60 and 90</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R)</measure>
    <time_frame>Screening, on Day 0 before the treatment (injection), on Day 30, Day 60, Day 90, at 6 months and 9 months</time_frame>
    <description>There are twelve questions, some asking about daily activities and how much help a patient needs with them, and some about specific symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Muscle Circumference</measure>
    <time_frame>Day 60, Day 90, at 6 months, and 9 months</time_frame>
    <description>Measurements will be taken bilaterally:
Mid-arm: at the midpoint of a vertical line that joins the acromion process to the olecranon process
Mid forearm: at the proximal one third point of a vertical line that joins the medial epicondyle to the styloid process of the ulna
Mid-thigh: midpoint of a vertical line that joins the anterior superior iliac spine to the superior edge of the patella
Mid-leg: at the proximal one third point of a vertical line that joins the fibular head to the lateral malleolus</description>
  </other_outcome>
  <other_outcome>
    <measure>Forced vital capacity</measure>
    <time_frame>Screening, on Day 0 before the treatment (injection), on Day 30, Day 60, Day 90, at 6 months and 9 month</time_frame>
    <description>pulmonary function test that quantifies the volume of air that can forcibly be blown out after full inspiration. It correlates with survival in ALS</description>
  </other_outcome>
  <other_outcome>
    <measure>muscle strength</measure>
    <time_frame>Day 30, Day 60, Day 90, at 6 months and 9 months</time_frame>
    <description>determined by using the Medical research Council (MRC) scale</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>VM202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total dose of 64 mg of VM202 It will be administered over the course of four visits: Day 0, Day 7, Day 14, and Day 21. As in all previous VM202 studies, final dose of VM202 for each target muscle group is divided and administered 2 weeks apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>VM202</intervention_name>
    <arm_group_label>VM202</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 21 years, but &lt; or = 75 years

          -  Subjects diagnosed with:

               -  clinically definite ALS,

               -  clinically probable ALS, or

               -  clinically probable-laboratory supported ALS as specified in the revised El
                  Escorial / Airlie House diagnostic criteria

          -  Onset of ALS &lt; 2 years at Screening

          -  Forced Vital Capacity (FVC) ≥ 60% of predicted

          -  Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) ≥ 30

          -  Not taking riluzole, or on a stable dose for at least thirty days prior to Screening
             (defined as no noted toxicities)

          -  Able and willing to give informed consent

          -  If female of childbearing potential, negative urine pregnancy test at Screening and
             using acceptable method of birth control during the study.

        Exclusion Criteria:

          -  Neurological symptom(s) due to vitamin B12 deficiency

          -  Requires tracheotomy ventilation or noninvasive ventilation &gt; 16 hours / day

          -  Comorbidities such as Parkinson's disease, schizophrenia, renal failure, or any other
             severe complication that, in the Investigator's opinion, will compromise the safety of
             the patient or confound interpretation of the data collected in this study

          -  Other neuromuscular disease

          -  Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's
             disease)

          -  Active infection

          -  Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis)

          -  Positive HIV or HTLV at Screening

          -  Active Hepatitis B or C as determined by Hepatitis B core antibody (HBcAb), antibody
             to Hepatitis B surface antigen (IgG and IgM; HBsAb), Hepatitis B surface antigen
             (HBsAg) and Hepatitis C antibodies (Anti-HCV) at Screening

          -  Subjects with known immunosuppression or currently receiving immunosuppressive drugs,
             chemotherapy or radiation therapy

          -  Stroke or myocardial infarction within last 3 months

          -  Patients with a recent history (&lt; 5 years) of malignant neoplasm except basal cell
             carcinoma or squamous cell carcinoma of the skin (if excised and no evidence of
             recurrence);

          -  Subjects requiring &gt; 81 mg daily of acetylsalicylic acid; subjects may be enrolled if
             willing/able to switch to ≤ 81 mg daily of acetylsalicylic acid or to another
             medication

          -  Subjects requiring regular COX-2 inhibitor drug(s) or non-specific COX-1/COX-2
             inhibiting drugs, or high dose steroids (excepting inhaled steroids); subjects may be
             enrolled if willing/able to undergo medication wash-out prior to the first dosing and
             to refrain from taking these drugs for the duration of the study

          -  Have used an investigational drug within 30 days of Screening

          -  Pregnant or currently lactating

          -  Major psychiatric disorder in past 6 months

          -  Known drug or alcohol dependence or any other factors which will interfere with the
             study conduct or interpretation of the results or who in the opinion of the
             Investigator are not suitable to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Kessler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Stem Cell Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2014</study_first_posted>
  <disposition_first_submitted>October 31, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>October 31, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 1, 2016</disposition_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Lou Gehrig's disease</keyword>
  <keyword>neurodegenerative disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

